Metabolic, Circadian trading halted ahead of trial results

By Staff Writers
Thursday, 09 December, 2004

Trading in shares of Metabolic Pharmaceuticals (ASX:MBP) and Circadian Technologies (ASX:CIR) was halted today, in advance of the release of data from Phase IIb trials of Metabolic's obesity drug, AOD9604.

Circadian is Metabolic's largest shareholder, owning 21 per cent of shares.

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...

Life expectancy gains are slowing, study finds

Life expectancy at birth in the world's longest-living populations has increased by an...

Towards safer epilepsy treatment for pregnant women

New research conducted in organoids is expected to provide pregnant women with epilepsy safer...

Content from other channels on our network

Seamless modular I/O integration

Coca-Cola invests nearly $100 million in Queensland manufacturing

Endress+Hauser receives IEC 62443‍-‍4‍-‍1 cybersecurity certification

NSW announces TAFE Centre of Excellence in the Hunter

CSP to power pet food manufacturing in Wodonga

Driving change: how electric vehicles are fuelling Australia's sustainable businesses

CSIRO gathers innovators to tackle plastic waste

Trinasolar launches agrivoltaics project in NZ

South East Water takes home R&D Excellence Award

Mars Petcare unveils renewable energy plan

Scooping Up Success: Sajani Cups and Cones Freezes Out Stock Issues with Fishbowl

Managing Food Safety Risk Efficiently with Data Automation

Introducing Tool-Free Mounting and Reduced Service Times with Bürkert's Direct Acting Service Valves

Hygiene-first cables and connectors for the food and beverage industry

Futurecasting Food Science with data